以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 肥胖已成为癌症的重要诱因，目前已知有超过13种癌症的发生与肥胖密切相关。作为仅次于吸烟的第二大可预防癌症风险因素，肥胖的危害不 容忽视。 然而，科学家们却发现一个令人困惑的现象：尽管肥胖会加速癌症的发生和进展，但在接受免疫治疗时，肥胖患者却往往表现出"保护效 应"——高BMI人群对免疫疗法的响应率更高，生存预后也更理想。 这究竟是肥胖隐藏的"善意"，还是背后藏着不为人知的机制？ 近日，范德堡大学的科研团队在《自然》杂志上发表了最新研究。他们发现，肥胖引发的炎性细胞因子会刺激肿瘤相关巨噬细胞（TAM）上 PD-1的表达，削弱了机体对肿瘤的免疫监视能力。虽然这种机制助推了癌症的发展，但同时也让抗PD-1免疫疗法有了更大的施展空间。 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 研究人员将小鼠分为两组，分别喂以低脂饮食（LFD，脂肪提供10%的能量）和高脂饮食（HFD，脂肪占比高达45%），喂食周期从6周龄 ...

Core Viewpoint - The article discusses the effectiveness and safety of Semaglutide in weight loss for patients with Inflammatory Bowel Disease (IBD), highlighting its comparable results to non-IBD patients and its advantages over other anti-obesity medications [4][7][10]. Group 1: Relationship Between Obesity and IBD - There is a complex relationship between obesity and IBD, where obesity may increase the incidence and complications of IBD [5]. - An estimated 41% of the U.S. population is obese, with nearly 1 in 100 diagnosed with IBD. Among IBD patients, 15% to 40% are obese, and 20% to 40% are overweight [6]. - Obesity, particularly visceral obesity, is a chronic inflammatory state of white adipose tissue, which may be a risk factor for developing IBD. Obese IBD patients have a higher risk of complications compared to non-obese IBD patients [6]. Group 2: Efficacy of Semaglutide - Semaglutide has shown significant and sustained weight loss effects in the general population, and a study indicates that IBD patients experience similar weight loss to non-IBD patients [7]. - A large study published in March 2021 found that individuals taking Semaglutide lost an average of 14.9% of their body weight over 68 weeks [7]. - A retrospective cohort study compared 47,424 obese IBD patients with 21,019 obese non-IBD patients, assessing overall weight changes after starting Semaglutide [9]. Group 3: Study Findings - The study matched 150 obese IBD patients with 150 obese non-IBD patients, with follow-up periods of 18 months for IBD and 19.4 months for non-IBD [9]. - The average total body weight (TBW) change for IBD and non-IBD groups was similar, with IBD patients losing an average of 16 pounds and non-IBD patients losing 15 pounds over 6 to 12 months [9]. - Semaglutide resulted in greater TBW loss compared to Liraglutide (-13 pounds vs -19 pounds) but less than Tirzepatide (-18 pounds vs -26 pounds) [10]. Group 4: Safety and Hospitalization Risks - There were no significant differences in the risk of emergency visits or hospitalization between the Semaglutide group and the non-Semaglutide group [10]. - The risk of hospitalization for any reason was significantly lower in the IBD Semaglutide group [10]. - The study aims to alleviate concerns regarding the efficacy and safety of Semaglutide for IBD patients [11].

整理 | GLP1减重宝典内容团队 GLP-1RA（胰高血糖素样肽-1 受体激动剂）是一种有助于调节血糖水平的药物，问世已有近 20 年，主要用于治疗糖尿病。然而随着最 近成功的临床试验结果公布，证明了 司美格鲁肽、替尔泊肽等某些 GLP-1RA 具有更广泛的健康益处，该药物引起了医学界、媒体和 商业界前所未有的关注。 复旦大学附属中山医院 李小英教授 曾对此 做了进一步阐述，GLP-1RA的多元作用机制与GLP-1受体在人体的广泛分布密切相关。 GLP-1受体分布于人体的多个重要器官和组织，如胰岛细胞、胃肠道、肾脏、下丘脑、心血管系统、肝脏以及脂肪细胞等。得益于此， GLP-1RA能够从多方面发挥降糖作用。 此外，李小英教授强调，糖尿病患者通常合并多种代谢紊乱，在此方面，GLP-1RA还能帮助患者管理体重、降低血压、改善血脂谱， 为患者整体健康带来了更加积极的影响，更为人们在糖尿病和相关代谢性疾病的早期治疗中增添了一层保障。 ▍ 技术赋能： SNAC助力司美格鲁肽实现口服给药 对于口服GLP-1RA的研发而言，如何避免药物进入胃肠道 被胃蛋白酶降解 是其主要挑战。司美格鲁肽片作为GLP-1RA家族的口服制 ...

Core Viewpoint - A recent large-scale study published in The Lancet Diabetes & Endocrinology indicates that excessive consumption of meat, particularly processed and red meat, significantly increases the risk of developing type 2 diabetes, with a recommendation for balanced dietary habits to mitigate this risk [6][9][12]. Group 1: Research Findings - The study analyzed dietary data from nearly 1.97 million adults across 20 countries, revealing that consuming 50 grams of processed meat daily could increase the risk of type 2 diabetes by 15% over ten years [9]. - Unprocessed red meat consumption of 100 grams daily (approximately a small steak) is associated with a 10% increase in diabetes risk [9][12]. - The research highlights a strong correlation between high meat consumption and diabetes risk, although it does not establish a direct causal relationship [7][12]. Group 2: Expert Recommendations - Nutritionists suggest that rather than completely eliminating meat, individuals should control their intake and incorporate more vegetables and whole grains into their diets to lower diabetes risk [7][9]. - The principle of moderation is emphasized, advocating for a balanced diet that allows for enjoyment of meat while prioritizing health [9][12]. Group 3: Biological Mechanisms - The study suggests that saturated fatty acids in red meat may interfere with insulin function, potentially leading to insulin resistance, which is a precursor to diabetes [13]. - Multiple factors, including saturated fats, nitrites, and harmful substances produced during high-temperature cooking, may contribute to the observed increase in diabetes risk [14].

整理 | GLP1减重宝典内容团队 美国联邦上诉法院周一驳回了诺和诺德（NOVOb.CO）对联邦医保药价谈判计划的挑战，这是制药企业在一系列诉讼中又一次败诉。 该计划允许美国医保体系（Medicare）与药企协商药品降价。 总部位于费城的第三巡回上诉法院维持了下级法院的裁决，驳回了这家丹麦制药商针对该计划及美国医疗保险和医疗补助服务中心 （CMS）决定将其六款胰岛素产品纳入首轮药价谈判的诉讼。 由三名法官组成的合议庭一致否决了诺和诺德提出的宪法异议，认为该计划是前民主党总统拜登《通胀削减法案》的一部分，且该法 律明确禁止法院审查被选入谈判名单的药品。 诺和诺德表示，正评估上诉的可能性。白宫方面尚未对此作出回应。 此项裁决巩固了联邦政府通过医保系统议价的权力。Medicare覆盖约6600万美国民众。尽管多家药企提起诉讼，首轮药价谈判仍在推 进，预计将于明年开始生效。 包括诺和诺德在内的多家制药公司曾声称，该计划侵犯了它们在正当程序和言论自由方面的宪法权利，但几乎全部败诉。 今年早些时候，同一上诉法院驳回了阿斯利康（AZN.L）、百时美施贵宝（BMY.N）和诺华（NOVN.S）的类似诉讼。法院认为，药 企并不享 ...

以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 数据显示，2021年全球20至79岁的成年人中，糖尿病患者人数已达5.37亿，预计到2045年将攀升至7.83亿。在这些患者中，2型糖尿病占比高 达96%，而且超过85%的2型糖尿病患者存在超重或肥胖问题。现有研究普遍认为，减重有助于缓解2型糖尿病，但具体效果尚存争议。 近日，柳叶刀子刊《The Lancet Diabetes & Endocrinology》发表了一项题为"体重减轻对2型糖尿病缓解的影响：随机对照试验的系统评价与 Meta回归分析"的研究（见图1）。本项系统性综述和Meta分析，深入剖析了减重幅度与2型糖尿病缓解之间的联系，为临床应用和公共健康政 策制定带来了重要参考。 01 • 研究概况 本研究严格遵循Cochrane和PRISMA指南，对全球范围内关于体重减重干预对2型糖尿病患者影响的随机对照试验进行了系统回顾和分析。主要 观察指标为干 ...

以下文章来源于内分泌早知道 ，作者关注内分泌的 内分泌早知道 . 核心发现： 1. 全球首次证实：GLP- 1 /GIP双受体激动剂Tir z e pa ti de能有效减少2型糖尿病患者肌肉脂肪沉积，同时保持肌肉量合理变化 深度分享内分泌用药经验、病例剖析、指南专业解读并紧跟国内外内分泌领域前沿进展，「每医健」旗下内容平台。 2. 5 2周治疗数据显示：患者体重显著降低同时，肌肉脂肪浸润程度明显改善，肌肉量变化与体重下降呈科学匹配 3. 创新研究方法：结合UK Bi oba nk近3000例真实世界数据，为临床结果提供精准参照系 研究价值与发表背景 这项具有里程碑意义的研究源自SURPASS- 3临床试验的MRI亚组分析，最新发表于《柳叶刀·糖尿病与内分泌学》2025年6月刊。研究 团队采用高精度MRI技术，系统对比了Tir z e pa ti de与德谷胰岛素治疗5 2周后，2型糖尿病患者大腿肌肉体积、脂肪浸润程度及标准化Z 分数的动态变化。 研究突破性地引入英国生物库大规模人群数据，首次建立了糖尿病药物治疗与肌肉健康变化的科学评价体系。这不仅为Tir z e p a ti de的 临床优势提供了影像学证 ...

Core Viewpoint - The article discusses the IPO application of Chengyi Biotechnology, highlighting its focus on developing oral small molecule drugs for unmet medical needs in cardiovascular metabolic and inflammatory diseases, particularly in weight management and related conditions [4]. Company Overview - Chengyi Biotechnology was established in 2018 and is currently in the clinical stage, aiming to address significant medical needs in the cardiovascular metabolic and inflammatory disease sectors [4]. - The company utilizes its proprietary TRANDD platform to develop a pipeline of products targeting obesity, metabolic-associated fatty liver disease (MASH), osteoarthritis pain, and other cardiovascular metabolic diseases [4]. Product Pipeline - The core candidate drug is ECC5004, an oral small molecule GLP-1 receptor agonist, which has the potential to be the second oral GLP-1 receptor agonist to be listed globally [6]. - Other products include ECC4703, a liver-targeting THR-β agonist expected to be a leading candidate for treating MASH, and ECC0509, an oral small molecule inhibitor of SSAO, which can be used in combination with GLP-1 receptor agonists [6]. Financial Performance - The projected revenues for Chengyi Biotechnology are approximately $36.06 million in 2023, $221 million in 2024, and $557,000 in the first half of 2025, with net profits of -$52.23 million, $139 million, and -$2.01 million for the same periods respectively [6]. - The company completed a $25 million Series C financing round at the end of 2023, with a post-money valuation of approximately $498 million [6]. Shareholding Structure - The latest shareholding structure includes significant stakes from various investors: Jianyi Capital (9.77%), Mifang Capital (5.47%), AstraZeneca (5.02%), and others [7]. Clinical Trials and Collaborations - The clinical pipeline includes ECC5004, which is in collaboration with AstraZeneca, with a total potential milestone payment of up to $1.2 billion, including various payments tied to clinical trial phases and regulatory approvals [8]. - The expected completion date for the trials of ECC5004 is in the fourth quarter of 2025, with additional milestones for further development and commercialization [8].

Core Viewpoint - The article discusses the effectiveness of personalized dosing of semaglutide in weight management, emphasizing its role in preventing weight regain when combined with lifestyle guidance and support [4][6]. Group 1: Research Findings - A recent study presented at the European Obesity Congress (ECO) highlights the advantages of using personalized doses of semaglutide in weight loss programs [4]. - The study involved 2,246 individuals in Denmark, primarily women with an average age of 49 and a BMI of 33.2, participating in a weight management program that included dietary advice, exercise, and psychological support [9]. - The average weight loss reported at week 64 was 14.8% (approximately 14.8 kg), and at week 76, it was 14.9% (approximately 14.9 kg) [12]. Group 2: Treatment Protocol - The standard dosing protocol for semaglutide is tailored to minimize side effects, starting with a lower initial dose and gradually increasing it based on individual progress [11]. - The average maximum dose of semaglutide used in the study was 0.77 mg, which is about one-third of the standard treatment protocol [12]. - At week 64, all patients reported a weight loss of over 5%, with 85.3% of patients losing more than 10% of their baseline weight [13]. Group 3: Side Effects and Management - While semaglutide is effective for weight loss, it can cause side effects such as diarrhea, nausea, and headaches [6]. - Recent findings suggest that patients receiving nutritional and exercise guidance alongside medication are less likely to experience weight regain after stopping the drug [6].

以下文章来源于肥胖世界ObesityWorld ，作者肥胖世界 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 研究团队构建了迄今最全面的脂肪组织单细胞图谱，涵盖171,247个细胞，样本来自25名极度肥胖者（术前及减重后）和24名健康瘦者，并结 合空间转录组数据（每组4人），聚焦与代谢异常紧密关联的腹部皮下脂肪。分析显示，肥胖脂肪组织中免疫细胞（尤其是巨噬细胞和淋巴细 胞）大量涌入，成熟脂肪细胞比例明显降低（暗示细胞死亡或更新不足）；而减重能有效缓解这些病理变化。 二、巨噬细胞的"记忆效应" 全球已有超10亿人被肥胖困扰。许多人以为"胖"仅是外表问题，殊不知腹部脂肪的异常实际上是代谢疾病的"隐形杀手"——它悄然引发胰岛素 抵抗、糖尿病、心血管疾病，甚至提高癌症风险。令人惊奇的是，减重能迅速扭转这些健康危机：血糖平稳了、血压下降了、血管恢复弹性 了。但科学界一直未能破解这一谜团：脂肪组织内部到底经历了什么变化？是细胞数量减少了？还是基因表达重新"洗牌"了？ 为揭开这一 ...